Covid-19 Isn’t Over: Hospitalizations Ups, Vaccines Down and Cannabis Reducing Symptoms? 

Between December 30th, 2023, and January 8, 2024, there were 34,7981 people hospitalized due to Covid-19. This is a big jump of 20.4%2 from the previous week. During the same period, emergency room visits for Covid-19 increased by 12.8%3, and there was a 12.5%4 rise in Covid-19-related deaths. These numbers highlight the ongoing impact of the virus in the U.S. 

This issue is not confined to the United States alone; it is a global concern. The World Health Organization (WHO) reported that nearly 10,000 people died from COVID-19 in December across approximately 50 countries, predominantly in Europe and the Americas. This surge was attributed to gatherings during the Christmas holiday period. Now, the new JN.1 variant has become the most reported coronavirus variant in the world. It is important to note that while JN-1 has no evidence of being the most severe variant, it may be more easily spread. 

Although the pandemic was declared over by the WHO in May 2023, the current number of preventable deaths is unacceptable. 

The official end of the pandemic has led to a misconception that Covid-19 is no longer a threat. Consequently, masks have disappeared in public areas, people are neglecting to isolate when sick, and fewer individuals are opting for vaccine boosters. Unfortunately, these behaviors have contributed to the recent surge in Covid-19 cases. 

Although Covid may not pose the same level of threat as in 2020, it is crucial to acknowledge that the pandemic is not over. It remains essential for individuals to stay proactive in protecting themselves against Covid-19. 

Covid & Cannabis 

Surprisingly, recent findings presented at the annual meeting of the American College of Chest Physicians indicate that individuals who use cannabis and contract Covid-19 may experience more favorable outcomes and reduced mortality compared to non-users. 

Examining data from over 320,000 individuals5, researchers discovered that cannabis users exhibited significantly lower mortality rates (2.9% compared to 13.5%) and reduced incidence of complications such as intubation, acute respiratory failure, and multiorgan failure. 

The study suggested that marijuana might possess the ability to impede viral entry into cells and inhibit the release of proinflammatory cytokines, potentially contributing to these positive effects. 

While additional research is essential to delve deeper into the correlation between cannabis use and Covid-19 outcomes, earlier studies have also hinted at a connection between cannabis consumption and milder Covid-19 severity, as well as potential preventive properties against the virus. 

Furthermore, this presents another potential health advantage associated with the consumption of cannabis. 

Healthcare Sector 2024 Outlook 

Despite its usual reputation as a defensive industry, healthcare stocks underperformed in 2023. Nonetheless, analysts are expressing optimism about a potential rebound in the overall sector in 2024, particularly in Biotech. 

Biotech has faced challenges since 2020, with much of 2023 being notably difficult. In recent months, however, there has been a gradual increase in stock prices, fueling hope that the sector may be on the verge of a positive turnaround. 

The last instance of experiencing three consecutive down years in the biotech sector was in 1992, and the subsequent year saw a remarkable upswing of about 60%. This historical pattern suggests that the current scenario may present an opportune time for investment. 

One specific biotech stock drawing attention in early 2024 is Vertex Pharmaceuticals (Nasdaq: VRTX). The company is set to release more data on its experimental non-opioid painkiller, VX-548, positioning it as a potential game-changer in the field. This experimental drug is seen as a rival to the established “gold standard” treatment, adding a layer of anticipation among investors. 

VRTX has already shown promise with a notable performance since January 11, 2023, boasting a 45.17% increase in its stock value. This positive trajectory further contributes to the growing confidence in the company’s potential and strengthens the argument for considering adding it to your watchlist.